Anavex Life Sciences Corp (AVXL)

[drv17]

MHPAEA "It is important for panelists such as Dr. Missling to attend in order to lend his expertise in developing therapies for diseases such as Alzheimer's disease as well as other neurological disorders with high unmet needs."

To refresh our memories, Dr. Missling has been invited to the annual MHPAEA Business Roundtable meeting twice. I haven't seen a representative from any big pharma or other bio-tech firm listed to attend either of these business round tables

Anavex Life Sciences To Present At The 5th Annual Mental Health Parity Addiction Equity Act Business Roundtable In Washington, DC
GlobeNewswire - Wed Nov 8, 6:01AM CST
Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer of Anavex, will be a panelist at the 5th Annual Mental Health Parity and Addiction Equity Act (MHPAEA) Business Roundtable. The event is taking place on Wednesday, November 8, 2017, at the United States Capitol Visitor Center, in Washington, DC.

"Mental health is an issue our nation must address, and the best way to do that is to continue to work together from all sides and educate our policy leaders," said E. Teresa Touey, organizer of the MHPAEA Business Roundtable. "It is important for panelists such as Dr. Missling to attend in orde to lend his expertise in developing therapies for diseases such as Alzheimer's disease as well as other neurological disorders with high unmet needs."

Anavex was previously invited to attend the 3rd Annual meeting of MHPAEA on Dec. 8th 2015. (Note the list of the other invited attendees)

NEW YORK, Dec. 07, 2015 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing drug candidates to treat Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, has been invited to speak at the third annual roundtable on the implementation of the Mental Health Parity Addiction and Equity Act (MHPAEA) of 2008. The event will take place on Tuesday, December 8, 2015 at the U.S. Capitol Visitor Center in Washington, D.C.

Dr. Missling will present an Alzheimer’s case study on the Anavex pipeline and share his experience in the field of the private sector that can translate to public investment support for brain research.

“Advancing research and establishing a better understanding of how we can potentially improve the treatment of Alzheimer’s patients and develop new medicines for other neurodegenerative diseases are critical milestones in helping more than 25 million people living with Alzheimer’s disease today. We are honored by the invitation to present to such an esteemed group,” said Dr. Missling.

Other confirmed attendees and speakers include eight members of the United States House of Representatives, including three who sit on the bipartisan Congressional Task Force on Alzheimer’s disease, experts from Cohen Veterans Bioscience, Johns Hopkins School of Medicine, Brigham and Women’s Hospital, GoldLab Foundation at University of Colorado Boulder, JFK Partners at University of Colorado School of Medicine and retired U.S. Army leadership